BIOLIFE SOLUTIONS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M | $76.2M | $119.2M |
| Gross profit | $62.1M | $50.1M | $41.3M | — | — |
| Operating income | -$16.6M | -$4.5M | -$17.2M | -$5.9M | -$35.2M |
| Cost of revenue | $34.1M | $24.6M | $26.7M | — | — |
| Cash from operations | $20.1M | $8.4M | -$12.5M | -$8.5M | -$4.6M |
| Capital expenditure | $9.5M | $3.2M | $6.4M | $10.4M | $8.4M |
| Free cash flow | $10.6M | $5.2M | -$18.9M | -$18.9M | -$13.0M |
| Impairments | $0 | $0 | $15.5M | $110.4M | $0 |
| Total assets | $405.9M | $399.5M | $412.7M | $450.2M | $554.3M |
| Total liabilities | $34.0M | $50.6M | $75.1M | $86.0M | $76.2M |
| Total debt | $5.0M | $16.0M | $23.9M | $25.8M | $7.2M |
Shares outstanding 48.9M · Free float 83.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.